[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601681":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":28,"locations":34,"responsibleParty":51,"collaborators":27,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":27,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":27,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":27,"overallStatus":36,"whyStopped":27,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Shanghai Mental Health Center","OTHER",[8,13,17],{"label":9,"type":6,"description":10,"interventionNames":11},"Nucleus Accumbens Group(NAcc)-Bed Nucleus of the Stria Terminalis Group(BNST)-Exploratory group","Participants assigned to NAcc-BNST group will receive stimulation targeting the NAcc in Phase 1 and the BNST in Phase 2. During the exploratory phase, based on participants' preferences, they will be randomly allocated to receive stimulation targeting one of the following regions: the caudate nucleus, the putamen, or the amygdala.",[12],"Device: TI stimulation device (nerviox-1000）",{"label":14,"type":6,"description":15,"interventionNames":16},"Bed Nucleus of the Stria Terminalis Group(BNST)-Nucleus Accumbens Group(NAcc)-Exploratory group","Participants assigned to BNST-NAcc group will receive stimulation targeting the BNST in Phase 1 and the NAcc in Phase 2. During the exploratory phase, based on participants' preferences, they will be randomly allocated to receive stimulation targeting one of the following regions: the caudate nucleus, the putamen, or the amygdala.",[12],{"label":18,"type":6,"description":19,"interventionNames":20},"Sham Group-NAcc Group or BNST Group-Exploratory group","Participants assigned to the Sham-NAcc or Sham-BNST groups will receive sham stimulation in Phase 1, followed by active stimulation targeting the NAcc or the BNST in Phase 2. During the exploratory phase, based on participants' preferences, they will be randomly allocated to receive stimulation targeting one of the following regions: the caudate nucleus, the putamen, or the amygdala.",[12],[22],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DEVICE","TI stimulation device (nerviox-1000）","The TI stimulation device (nerviox-1000) delivers temporally interfering electrical fields with a 130 Hz envelope frequency, generated by high-frequency carrier waves. The stimulation is applied for 20 minutes per session, with a peak current of 3-4 mA per channel, adjusted based on individual tolerance. The stimulation targets include the nucleus accumbens, bed nucleus of the stria terminalis, amygdala, caudate nucleus, and putamen. Stimulation is administered twice daily, with each treatment phase lasting 7 consecutive days.\n\nSham stimulation uses identical electrode placement and setup as active stimulation. A brief 30-second ramp-up is applied to mimic real stimulation, followed by rapid reduction to 0 mA or minimal current. A 1 mA \"tail\" current is delivered in the final 30 seconds to simulate the tapering effect of active stimulation.",[14,9,18],null,[29],{"name":30,"role":31,"phone":32,"phoneExt":27,"email":33},"Zhen Wang, PhD,MD","CONTACT","+86 34773516","wangzhen@smhc.org.cn",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Shanghai","Shanghai Municipality","200030","China","CN",{"type":43,"coordinates":44},"Point",[45,46],121.45806,31.22222,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":32,"phoneExt":27,"email":33},"Zhen Wang, Phd, MD",{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Zhen Wang","vice-president","100601681","the-efficacy-of-temporal-interference-stimulation-in-the-treatment-of-obsessive-compulsive-disorder-100601681",false,"NCT07113652","The Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder","Exploring the Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder","Inclusion Criteria:\n\n* 18-50 years old\n* Diagnosis of OCD per DSM-5\n* Y-BOCS score ≥20\n* Have a documented history of at least two adequate trials of selective serotonin reuptake inhibitors (SSRIs). If currently receiving SSRI treatment, the dosage must be stable for at least 8 weeks prior to enrollment\n* With at least 9 years of education\n\nExclusion Criteria:\n\n* Any DSM-5 diagnosis other than OCD (except OCPD)\n* OCD symptoms too severe to complete assessments\n* Received electroconvulsive therapy (ECT) within the past 6 months\n* Received other forms of neuromodulation within the past 2 months（see Item 3 for ECT）\n* Severe medical illness or seizure risk (e.g., cardiovascular, respiratory conditions)\n* Neurological disorders or history of brain injury\u002Fsurgery\n* MRI-incompatible implants (e.g., pacemaker, stents, cochlear implants).\n* Current suicidal risk per investigator judgment\n* Pregnant or planning pregnancy during the study\n* Started structured OCD psychotherapy within 3 months, with expected change during treatment","ALL","18 Years","50 Years",{"count":66,"type":67},18,"ESTIMATED","INTERVENTIONAL",[70],"NA","This study aims to evaluate the efficacy of Temporal Interference (TI) stimulation in treating patients with obsessive-compulsive disorder (OCD) and to explore its potential neural mechanisms using magnetic resonance imaging (MRI) and electroencephalography (EEG).",[73],"Obsessive-Compulsive Disorder (OCD)","2026-03-07",{"date":76,"type":77},"2026-03-10","ACTUAL",{"date":79,"type":77},"2025-08-17",{"date":81,"type":67},"2027-06",{"name":5,"class":6},1]